Cancer Family
Myeloid Neoplasm
CI-CAN-00000279Explore in graph →
HematologicNon-malignant1,103 active trials29 approved drugs653 evidence items
Loading cancer entity…
Cancer Family
CI-CAN-00000279Explore in graph →
Clinical trials
4,792 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT05805605 | Allo HSCT Using RIC and PTCy for Hematological Diseases | recruiting | Phase 2 | 56 | Masonic Cancer Center, University of MinnesotaOTHER | 1 | Jul 6, 2026 | clinicaltrials |
| NCT07304011 | Olutasidenib With Azacitidine Followed by Olutasidenib Maintenance for the Treatment of IDH1-mutated Acute Myeloid Leukemia in Patients With Prior Treatment With Venetoclax Plus a Hypomethylating Agent | recruiting | Phase 2 | 28 | University of California, DavisOTHER | 1 | Jul 2, 2026 |
| clinicaltrials |
| NCT07680933 | Orelabrutinib Combined With Standard Immunochemotherapy With or Without Autologous Hematopoietic Stem Cell Transplantation (Auto-HSCT) for Newly Diagnosed Diffuse Large B-cell Lymphoma (DLBCL) | recruiting | Phase 2 | 30 | The Affiliated Hospital of Xuzhou Medical UniversityOTHER | 1 | Jul 2, 2026 | clinicaltrials |
| NCT00658814 | Azacitidine and Gemtuzumab Ozogamicin in Treating Older Patients With Previously Untreated Acute Myeloid Leukemia | active not recruiting | Phase 2 | 133 | National Cancer Institute (NCI)NIH | 1 | Jul 1, 2026 | clinicaltrials |
| NCT02094794 | Total Marrow and Lymphoid Irradiation and Chemotherapy Before DSCT in Treating Patients With High-Risk ALL or AML | active not recruiting | Phase 2 | 108 | City of Hope Medical CenterOTHER | 1 | Jul 1, 2026 | clinicaltrials |
| NCT03722407 | Ruxolitinib for the Treatment of Chronic Myelomonocytic Leukemia (CMML): A Phase 2 Expansion | active not recruiting | Phase 2 | 29 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Jul 1, 2026 | clinicaltrials |
| NCT04050280 | CLAG-GO for Patients With Persistent, Relapsed or Refractory AML | recruiting | Phase 2 | 39 | University of Maryland, BaltimoreOTHER | 1 | Jul 1, 2026 | clinicaltrials |
| NCT04195555 | Ivosidenib in Treating Patients With Advanced Solid Tumors, Lymphoma, or Histiocytic Disorders With IDH1 Mutations (A Pediatric MATCH Treatment Trial) | active not recruiting | Phase 2 | 3 | National Cancer Institute (NCI)NIH | 3 | Jul 1, 2026 | clinicaltrials |
| NCT07007052 | Phase II Study Evaluating the Efficacy and Safety of the Combination of Tagraxofusp and Venetoclax in Treatment-naive Blastic Plasmacytoid Dendritic Cell Neoplasm Patients(TAGVEN) | recruiting | Phase 2 | 33 | French Innovative Leukemia OrganisationOTHER | 1 | Jul 1, 2026 | clinicaltrials |
| NCT07677813 | Orelabrutinib Combined With Induction Therapy Followed by Sequential Monotherapy Maintenance in MCD Subtype Diffuse Large B-cell Lymphoma | not yet recruiting | Phase 2 | 66 | Ou Bai, MD/PHDOTHER | 1 | Jul 1, 2026 | clinicaltrials |
| NCT04802161 | Comparing the Addition of an Anti-Cancer Drug, Pomalidomide, to the Usual Chemotherapy Treatment (Daunorubicin and Cytarabine Liposome) in Newly Diagnosed Acute Myeloid Leukemia With Myelodysplastic Syndrome-Related Changes | active not recruiting | Phase 2 | 49 | National Cancer Institute (NCI)NIH | 1 | Jun 30, 2026 | clinicaltrials |
| NCT07597941 | Lisaftoclax for Prevention of Differentiation Syndrom in Acute Promyelocytic Leukemia Patients | not yet recruiting | Phase 2 / Phase 3 | 20 | The Affiliated People's Hospital of Ningbo UniversityOTHER_GOV | 0 | Jun 30, 2026 | clinicaltrials |
| NCT06815003 | Vedolizumab Plus Post-transplant Cyclophosphamide and Short Course Tacrolimus for the Prevention of Graft Versus Host Disease in Patients Undergoing Allogeneic Hematopoietic Cell Transplantation After Reduced Intensity Conditioning | recruiting | Phase 2 | 35 | City of Hope Medical CenterOTHER | 1 | Jun 29, 2026 | clinicaltrials |
| NCT07528417 | Evaluation of Antibiotic Prophylaxis in Myelodysplastic Syndromes and Acute Myeloid Leukemia (MYELO-CAN:ABX)(MYELO-CAN:ABX) | not yet recruiting | Phase 2 | 75 | University of ManitobaOTHER | 1 | Jun 29, 2026 | clinicaltrials |
| NCT06802315 | Intensity Modulated Total Marrow Irradiation in Fully Human Leukocyte Antigen (HLA)-Matched and Partially-HLA Mismatched Allogeneic Transplantation Patients With High-Risk Acute Myeloid Leukemia (AML), Chronic Myeloid Leukemia (CML), and Myelodysplastic Syndrome (MDS)(BMT-13) | recruiting | Phase 2 | 38 | University of Illinois at ChicagoOTHER | 1 | Jun 26, 2026 | clinicaltrials |
| NCT03314974 | Myeloablative Allo HSCT With Related or Unrelated Donor for Heme Disorders | recruiting | Phase 2 | 300 | Masonic Cancer Center, University of MinnesotaOTHER | 1 | Jun 25, 2026 | clinicaltrials |
| NCT05656248 | Study of CPX-351 (VYXEOS) in Individuals < 22 Years With Secondary Myeloid Neoplasms | active not recruiting | Phase 2 | 25 | St. Jude Children's Research HospitalOTHER | 1 | Jun 25, 2026 | clinicaltrials |
| NCT04068597 | Study to Evaluate CCS1477 (Inobrodib) in Haematological Malignancies | recruiting | Phase 1 / Phase 2 | 250 | CellCentric Ltd.INDUSTRY | 5 | Jun 24, 2026 | clinicaltrials |
| NCT07664839 | Study on the Efficacy and Safety of VA Regimen Compared to "3+7" Regimen in Newly Diagnosed AML With NPM1 or IDH1/IDH2 Mutations | not yet recruiting | Phase 2 | 148 | Shen yangOTHER | 1 | Jun 24, 2026 | clinicaltrials |
| NCT03289910 | Topotecan Hydrochloride and Carboplatin With or Without Veliparib in Treating Advanced Myeloproliferative Disorders and Acute Myeloid Leukemia or Chronic Myelomonocytic Leukemia | active not recruiting | Phase 2 | 25 | National Cancer Institute (NCI)NIH | 1 | Jun 23, 2026 | clinicaltrials |
| NCT07572929 | A Pragmatic Clinical Trial to Prevent Relapse for Myeloid Malignancies With Measurable Disease Prior to Allogeneic Transplant(PREeMPT) | not yet recruiting | Phase 2 | 450 | Medical College of WisconsinOTHER | 1 | Jun 23, 2026 | clinicaltrials |
| NCT03128034 | 211^At-BC8-B10 Before Donor Stem Cell Transplant in Treating Patients With High-Risk Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Myelodysplastic Syndrome, or Mixed-Phenotype Acute Leukemia | recruiting | Phase 1 / Phase 2 | 75 | Fred Hutchinson Cancer CenterOTHER | 1 | Jun 22, 2026 | clinicaltrials |
| NCT03670966 | 211At-BC8-B10 Followed by Donor Stem Cell Transplant in Treating Patients With Relapsed or Refractory High-Risk Acute Leukemia or Myelodysplastic Syndrome | recruiting | Phase 1 / Phase 2 | 30 | Fred Hutchinson Cancer CenterOTHER | 1 | Jun 22, 2026 | clinicaltrials |
| NCT04581512 | Study to Evaluate the Safety and Tolerability of EP0042 | recruiting | Phase 1 / Phase 2 | 70 | Ellipses PharmaINDUSTRY | 3 | Jun 22, 2026 | clinicaltrials |
| NCT07356154 | A Study of Revumenib and Mezigdomide in People With Leukemia | recruiting | Phase 1 / Phase 2 | 52 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Jun 22, 2026 | clinicaltrials |
| NCT07563010 | Menin-Inhibitor Targeted Maintenance in AML | not yet recruiting | Phase 2 | 146 | Center for International Blood and Marrow Transplant ResearchNETWORK | 0 | Jun 22, 2026 | clinicaltrials |
| NCT03441113 | Extended Access of Momelotinib in Adults With Myelofibrosis | active not recruiting | Phase 2 | 237 | GlaxoSmithKlineINDUSTRY | 20 | Jun 18, 2026 | clinicaltrials |
| NCT06707493 | Ivosidenib as Post-HSCT Maintenance for AML | recruiting | Phase 2 | 75 | Massachusetts General HospitalOTHER | 1 | Jun 18, 2026 | clinicaltrials |
| NCT07643636 | Chidamide, Venetoclax, Azacitidine, and Homoharringtonine for High-risk Fit AML | not yet recruiting | Phase 2 | 46 | Dongguan People's HospitalOTHER_GOV | 0 | Jun 18, 2026 | clinicaltrials |
| NCT03213704 | Larotrectinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With NTRK Fusions (A Pediatric MATCH Treatment Trial) | active not recruiting | Phase 2 | 9 | National Cancer Institute (NCI)NIH | 2 | Jun 17, 2026 | clinicaltrials |
| NCT07651163 | Comparing the Efficacy of LDA, LHAA, and LA Regimens in Young Adults With Intermediate- and High-Risk Acute Myeloid Leukemia Eligible for Intensive Chemotherapy | enrolling by invitation | Phase 2 / Phase 3 | 450 | First Affiliated Hospital of Zhejiang UniversityOTHER | 1 | Jun 16, 2026 | clinicaltrials |
| NCT07651176 | Comparing the Efficacy of the LDA, LHAA, and DA Regimens in Young Adults With Low-Risk Acute Myeloid Leukemia Eligible for Intensive Chemotherapy | enrolling by invitation | Phase 2 / Phase 3 | 267 | First Affiliated Hospital of Zhejiang UniversityOTHER | 1 | Jun 16, 2026 | clinicaltrials |
| NCT04047641 | Cladribine, Idarubicin, Cytarabine, and Quizartinib in Treating Patients With Newly Diagnosed, Relapsed, or Refractory Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome | recruiting | Phase 1 / Phase 2 | 80 | M.D. Anderson Cancer CenterOTHER | 1 | Jun 12, 2026 | clinicaltrials |
| NCT04668885 | CPX-351 as a Novel Approach for the Treatment of Older Patients With AML and MDS | active not recruiting | Phase 2 | 13 | Case Comprehensive Cancer CenterOTHER | 1 | Jun 12, 2026 | clinicaltrials |
| NCT03622788 | Cytokine-Treated Veto Cells in Treating Patients With Hematologic Malignancies Following Stem Cell Transplant | active not recruiting | Phase 1 / Phase 2 | 16 | M.D. Anderson Cancer CenterOTHER | 1 | Jun 11, 2026 | clinicaltrials |
| NCT04517851 | Elotuzumab for the Treatment of JAK2-Mutated Myelofibrosis | active not recruiting | Phase 2 | 15 | M.D. Anderson Cancer CenterOTHER | 1 | Jun 11, 2026 | clinicaltrials |
| NCT07642453 | VA-CAG Two-Week vs. Three-Week Regimen for Induction Remission in Newly Diagnosed Acute Myeloid Leukemia. | not yet recruiting | Phase 2 | 110 | Hematology department of the 920th hospitalOTHER | 0 | Jun 11, 2026 | clinicaltrials |
| NCT03247088 | Sorafenib, Busulfan and Fludarabine in Treating Patients With Recurrent or Refractory Acute Myeloid Leukemia Undergoing Donor Stem Cell Transplant | active not recruiting | Phase 1 / Phase 2 | 74 | M.D. Anderson Cancer CenterOTHER | 1 | Jun 10, 2026 | clinicaltrials |
| NCT07575412 | SHR2554/AZA + Overlapped Modified BUCY for High-risk/Relapsed Leukemia/MDS | not yet recruiting | Phase 2 | 180 | The First Affiliated Hospital of Soochow UniversityOTHER | 1 | Jun 10, 2026 | clinicaltrials |
| NCT07636564 | Testing Blinatumomab With or Without Revumenib in Patients With B-cell Acute Lymphoblastic Leukemia With a Genetic Change Requiring More Treatment | not yet recruiting | Phase 2 | 90 | SWOG Cancer Research NetworkNETWORK | 0 | Jun 9, 2026 | clinicaltrials |
| NCT03586609 | Venetoclax, Cladribine, Low Dose Cytarabine, and Azacitidine in Treating Patients With Previously Untreated Acute Myeloid Leukemia | recruiting | Phase 2 | 145 | M.D. Anderson Cancer CenterOTHER | 1 | Jun 8, 2026 | clinicaltrials |
| NCT05800210 | Alpha/Beta T Cell and CD19+ B Cell Depletion in Allogeneic Stem Cell Transplantation in Patients With Malignant Diseases | recruiting | Phase 2 | 20 | University of FloridaOTHER | 1 | Jun 4, 2026 | clinicaltrials |
| NCT07626021 | Selinexor Monotherapy for Cytoreduction in BCR::ABL1-Negative Myeloproliferative Neoplasms | not yet recruiting | Phase 2 | 15 | Zhongshan Hospital (Xiamen), Fudan UniversityOTHER | 0 | Jun 4, 2026 | clinicaltrials |
| NCT05364762 | Adding Itacitinib to Cyclophosphamide and Tacrolimus for the Prevention of Graft Versus Host Disease in Patients Undergoing Hematopoietic Stem Cell Transplants | active not recruiting | Phase 2 | 20 | City of Hope Medical CenterOTHER | 1 | Jun 3, 2026 | clinicaltrials |
| NCT07612280 | Phase 1/ Phase 2 Study to Assess Safety and Efficacy of Orally Administered JBI-802 in Subjects With Myeloproliferative Neoplasms (MPN) and Myelodysplastic/Myeloproliferative Neoplasms (MDS/MPN) With Thrombocytosis | recruiting | Phase 1 / Phase 2 | 30 | Jubilant Therapeutics Inc.INDUSTRY | 1 | Jun 3, 2026 | clinicaltrials |
| NCT07623616 | A Phase 2 Clinical Study of Ziftomenib in Patients With Relapsed or Refractory NPM1-Mutated Acute Myeloid Leukemia | recruiting | Phase 2 | 6 | Kyowa Kirin Co., Ltd.INDUSTRY | 1 | Jun 3, 2026 | clinicaltrials |
| NCT00544115 | Donor Peripheral Stem Cell Transplant in Treating Patients With Advanced Hematologic Cancer or Other Disorders | active not recruiting | Phase 2 | 260 | City of Hope Medical CenterOTHER | 0 | Jun 2, 2026 | clinicaltrials |
Data updated 23 days agoSource updated Jul 6, 2026source: clinicaltrials